Chemistry

Multiscale engineering of immune cells and lymphoid organs


1.

Joshi, N. S. et al. Regulatory T cells in tumor-associated tertiary lymphoid buildings suppress anti-tumor T cell responses. Immunity 43, 579–590 (2015).

2.

Li, W. et al. Bronchus-associated lymphoid tissue-resident Foxp3+ T lymphocytes forestall antibody-mediated lung rejection. J. Clin. Make investments. 129, 556–568 (2019).

three.

Garcia-Hernandez, M. L. et al. A singular mobile and molecular microenvironment is current in tertiary lymphoid organs of sufferers with spontaneous prostate most cancers regression. Entrance. Immunol. eight, 563 (2017).

Four.

Eddens, T. et al. Pneumocystis-driven inducible bronchus-associated lymphoid tissue formation requires Th2 and Th17 immunity. Cell Rep. 18, 3078–3090 (2017).

5.

Neelapu, S. S. et al. Chimeric antigen receptor T cell remedy — evaluation and administration of toxicities. Nat. Rev. Clin. Oncol. 15, 47–62 (2018). On this Assessment, the authors talk about mobile immunotherapy and supply suggestions for monitoring, grading and managing acute toxicities that may happen in sufferers.

6.

Weiner, G. J. Constructing higher monoclonal antibody-based therapeutics. Nat. Rev. Most cancers 15, 361–370 (2015).

7.

Chan, A. C. & Carter, P. J. Therapeutic antibodies for autoimmunity and irritation. Nat. Rev. Immunol. 10, 301–316 (2010).

eight.

Burak, M. F. et al. Improvement of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to deal with kind 2 diabetes. Sci. Transl Med. 7, 319ra205 (2015).

9.

Harrison, C. Autoimmune illness: focusing on IL-7 reverses kind 1 diabetes. Nat. Rev. Drug Discov. 11, 599 (2012).

10.

Penaranda, C. et al. IL-7 receptor blockade reverses autoimmune diabetes by selling inhibition of effector/reminiscence T cells. Proc. Natl Acad. Sci. USA 109, 12668–12673 (2012).

11.

Li, W. et al. A neutralizing anti-Nogo66 receptor monoclonal antibody reverses inhibition of neurite outgrowth by central nervous system myelin. J. Biol. Chem. 279, 43780–43788 (2004).

12.

Mothe, A. J. et al. RGMa inhibition with human monoclonal antibodies promotes regeneration, plasticity and restore, and attenuates neuropathic ache after spinal wire harm. Sci. Rep. 7, 10529 (2017).

13.

Tran, H. T. et al. Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep. 7, 2054–2065 (2014).

14.

Stephenson, R. & Singh, A. Drug discovery and therapeutic supply for the remedy of B and T cell tumors. Adv. Drug Deliv. Rev. 114, 285–300 (2017).

15.

Tokatlian, T. et al. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal facilities. Science 363, 649–654 (2019).

16.

Wilson, D. S. et al. Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protecting humoral and mobile immunity. Nat. Mater. 18, 175–185 (2019).

17.

Mosquera, M. J. et al. Immunomodulatory nanogels overcome restricted immunity in a murine mannequin of intestine microbiome-mediated metabolic syndrome. Sci. Adv. 5, eaav9788 (2019).

18.

Crane, G. M., Jeffery, E. & Morrison, S. J. Grownup haematopoietic stem cell niches. Nat. Rev. Immunol. 17, 573–590 (2017).

19.

Gordon, J. & Manley, N. R. Mechanisms of thymus organogenesis and morphogenesis. Improvement 138, 3865–3878 (2011).

20.

Morrison, S. J. & Scadden, D. T. The bone marrow area of interest for haematopoietic stem cells. Nature 505, 327–334 (2014). This paper describes the present understanding and controversies relating to the mobile composition and localization of haematopoietic stem cell niches throughout the bone marrow.

21.

Nagasawa, T. Microenvironmental niches within the bone marrow required for B cell improvement. Nat. Rev. Immunol. 6, 107–116 (2006).

22.

Wilson, A. & Trumpp, A. Bone-marrow haematopoietic-stem-cell niches. Nat. Rev. Immunol. 6, 93–106 (2006).

23.

Chabannon, C. et al. Hematopoietic stem cell transplantation in its 60s: a platform for mobile therapies. Sci. Transl Med. 10, eaap9630 (2018).

24.

Cornelissen, J. J. et al. The European LeukemiaNet AML Working Get together consensus assertion on allogeneic HSCT for sufferers with AML in remission: an integrated-risk tailored method. Nat. Rev. Clin. Oncol. 9, 579–590 (2012).

25.

Atkins, H. L. et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive a number of sclerosis: a multicentre single-group part 2 trial. Lancet 388, 576–585 (2016).

26.

Kawai, T. et al. Lengthy-term ends in recipients of mixed HLA-mismatched kidney and bone marrow transplantation with out upkeep immunosuppression. Am. J. Transplant. 14, 1599–1611 (2014).

27.

Ogonek, J. et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Entrance. Immunol. 7, 507 (2016).

28.

Bello, A. B., Park, H. & Lee, S. H. Present approaches in biomaterial-based hematopoietic stem cell niches. Acta Biomater. 72, 1–15 (2018).

29.

Chinn, I. Okay., Blackburn, C. C., Manley, N. R. & Sempowski, G. D. Modifications in main lymphoid organs with growing old. Semin. Immunol. 24, 309–320 (2012).

30.

Itkin, T. et al. Distinct bone marrow blood vessels differentially regulate haematopoiesis. Nature 532, 323–328 (2016).

31.

Kunisaki, Y. et al. Arteriolar niches keep haematopoietic stem cell quiescence. Nature 502, 637–643 (2013).

32.

Braccini, A. et al. Three-dimensional perfusion tradition of human bone marrow cells and technology of osteoinductive grafts. Stem Cells 23, 1066–1072 (2005).

33.

Ferreira, M. S. et al. Twine blood-hematopoietic stem cell growth in 3D fibrin scaffolds with stromal help. Biomaterials 33, 6987–6997 (2012).

34.

Leisten, I. et al. 3D co-culture of hematopoietic stem and progenitor cells and mesenchymal stem cells in collagen scaffolds as a mannequin of the hematopoietic area of interest. Biomaterials 33, 1736–1747 (2012).

35.

Miyoshi, H., Murao, M., Ohshima, N. & Tun, T. Three-dimensional tradition of mouse bone marrow cells inside a porous polymer scaffold: results of oxygen focus and stromal layer on growth of haematopoietic progenitor cells. J. Tissue Eng. Regen. Med. 5, 112–118 (2011).

36.

Mortera-Blanco, T., Mantalaris, A., Bismarck, A., Aqel, N. & Panoskaltsis, N. Lengthy-term cytokine-free growth of wire blood mononuclear cells in three-dimensional scaffolds. Biomaterials 32, 9263–9270 (2011).

37.

Nichols, J. E. et al. In vitro analog of human bone marrow from 3D scaffolds with biomimetic inverted colloidal crystal geometry. Biomaterials 30, 1071–1079 (2009).

38.

Raic, A., Rodling, L., Kalbacher, H. & Lee-Thedieck, C. Biomimetic macroporous PEG hydrogels as 3D scaffolds for the multiplication of human hematopoietic stem and progenitor cells. Biomaterials 35, 929–940 (2014).

39.

Feng, Q., Chai, C., Jiang, X. S., Leong, Okay. W. & Mao, H. Q. Enlargement of engrafting human hematopoietic stem/progenitor cells in three-dimensional scaffolds with surface-immobilized fibronectin. J. Biomed. Mater. Res. A 78, 781–791 (2006).

40.

Nilsson, S. Okay. et al. Immunofluorescence characterization of key extracellular matrix proteins in murine bone marrow in situ. J. Histochem. Cytochem. 46, 371–377 (1998).

41.

Choi, J. S. & Harley, B. A. Marrow-inspired matrix cues quickly have an effect on early destiny choices of hematopoietic stem and progenitor cells. Sci. Adv. three, e1600455 (2017).

42.

Kotov, N. A. et al. Inverted colloidal crystals as three-dimensional cell scaffolds. Langmuir 20, 7887–7892 (2004).

43.

Huang, X. et al. Co-cultured hBMSCs and HUVECs on human bio-derived bone scaffolds present help for the long-term ex vivo tradition of HSC/HPCs. J. Biomed. Mater. Res. A 104, 1221–1230 (2016).

44.

Ronaldson-Bouchard, Okay. & Vunjak-Novakovic, G. Organs-on-a-Chip: a quick observe for engineered human tissues in drug improvement. Cell Stem Cell 22, 310–324 (2018).

45.

Mahadik, B. P., Wheeler, T. D., Skertich, L. J., Kenis, P. J. & Harley, B. A. Microfluidic technology of gradient hydrogels to modulate hematopoietic stem cell tradition setting. Adv. Healthc. Mater. three, 449–458 (2014).

46.

Torisawa, Y. S. et al. Bone marrow-on-a-chip replicates hematopoietic area of interest physiology in vitro. Nat. Strategies 11, 663–669 (2014). On this research, the authors report an engineered bone-marrow-on-chip that recapitulates organ-level toxicity responses and protecting results of radiation countermeasure medication.

47.

Rodling, L. et al. 3D fashions of the hematopoietic stem cell area of interest underneath steady-state and lively situations. Sci. Rep. 7, 4625 (2017).

48.

Bourgine, P. E. et al. In vitro biomimetic engineering of a human hematopoietic area of interest with purposeful properties. Proc. Natl Acad. Sci. USA 115, E5688–E5695 (2018).

49.

Di Buduo, C. A. et al. Modular movement chamber for engineering bone marrow structure and performance. Biomaterials 146, 60–71 (2017).

50.

Di Buduo, C. A. et al. Programmable 3D silk bone marrow area of interest for platelet technology ex vivo and modeling of megakaryopoiesis pathologies. Blood 125, 2254–2264 (2015).

51.

Shepherd, J. H. et al. Structurally graduated collagen scaffolds utilized to the ex vivo technology of platelets from human pluripotent stem cell-derived megakaryocytes: enhancing manufacturing and purity. Biomaterials 182, 135–144 (2018).

52.

Tozzi, L. et al. Multi-channel silk sponge mimicking bone marrow vascular area of interest for platelet manufacturing. Biomaterials 178, 122–133 (2018).

53.

Braham, M. V. J. et al. Endosteal and perivascular subniches in a 3D bone marrow mannequin for a number of myeloma. Tissue Eng. Half C Strategies 24, 300–312 (2018).

54.

Braham, M. V. J. et al. Mobile immunotherapy on main a number of myeloma expanded in a 3D bone marrow area of interest mannequin. Oncoimmunology 7, e1434465 (2018).

55.

Reagan, M. R. et al. Investigating osteogenic differentiation in a number of myeloma utilizing a novel 3D bone marrow area of interest mannequin. Blood 124, 3250–3259 (2014).

56.

Shih, Y. R. et al. In vivo engineering of bone tissues with hematopoietic capabilities and blended chimerism. Proc. Natl Acad. Sci. USA 114, 5419–5424 (2017).

57.

Shah, N. J. et al. An injectable bone marrow-like scaffold enhances T cell immunity after hematopoietic stem cell transplantation. Nat. Biotechnol. https://doi.org/10.1038/s41587-019-0017-2 (2019).

58.

Fan, Y. et al. Bioengineering thymus organoids to revive thymic operate and induce donor-specific immune tolerance to allografts. Mol. Ther. 23, 1262–1277 (2015).

59.

Tajima, A., Pradhan, I., Trucco, M. & Fan, Y. Restoration of thymus operate with bioengineered thymus organoids. Curr. Stem Cell Rep. 2, 128–139 (2016).

60.

Palmer, D. B. The impact of age on thymic operate. Entrance. Immunol. Four, 316 (2013).

61.

Neelapu, S. S. et al. Kte-C19 (anti-CD19 CAR T Cells) induces full remissions in sufferers with refractory diffuse massive B-cell lymphoma (DLBCL): outcomes from the pivotal part 2 zuma-1. Blood 128, LBA-6 (2016).

62.

Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).

63.

Fischbach, M. A., Bluestone, J. A. & Lim, W. A. Cell-based therapeutics: the subsequent pillar of drugs. Sci. Transl Med. 5, 179ps177 (2013).

64.

Rosenberg, S. A. & Restifo, N. P. Adoptive cell switch as personalised immunotherapy for human most cancers. Science 348, 62–68 (2015).

65.

Hare, Okay. J., Jenkinson, E. J. & Anderson, G. In vitro fashions of T cell improvement. Semin. Immunol. 11, three–12 (1999).

66.

Dallas, M. H., Varnum-Finney, B., Delaney, C., Kato, Okay. & Bernstein, I. D. Density of the Notch ligand Delta1 determines technology of B and T cell precursors from hematopoietic stem cells. J. Exp. Med. 201, 1361–1366 (2005).

67.

Dallas, M. H., Varnum-Finney, B., Martin, P. J. & Bernstein, I. D. Enhanced T cell reconstitution by hematopoietic progenitors expanded ex vivo utilizing the Notch ligand Delta1. Blood 109, 3579–3587 (2007).

68.

Varnum-Finney, B. et al. Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J. Cell Sci. 23, 4313–4318 (2000).

69.

Schmitt, T. M. et al. Induction of T cell improvement and institution of T cell competence from embryonic stem cells differentiated in vitro. Nat. Immunol. 5, 410–417 (2004).

70.

Schmitt, T. M. & Zuniga-Pflucker, J. C. Induction of T cell improvement from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 17, 749–756 (2002).

71.

Taqvi, S., Dixit, L. & Roy, Okay. Biomaterial-based notch signaling for the differentiation of hematopoietic stem cells into T cells. J. Biomed. Mater. Res. A 79, 689–697 (2006).

72.

Shukla, S. et al. Progenitor T cell differentiation from hematopoietic stem cells utilizing Delta-like-Four and VCAM-1. Nature Strategies 14, 531–538 (2017).

73.

Mohtashami, M. & Zuniga-Pflucker, J. C. Three-dimensional structure of the thymus is required to keep delta-like expression crucial for inducing T cell improvement. J. Immunol. 176, 730–734 (2006).

74.

Seet, C. S. et al. Technology of mature T cells from human hematopoietic stem and progenitor cells in synthetic thymic organoids. Nat. Strategies 14, 521–530 (2017). On this paper, the authors report on synthetic thymic organoids for steering human HSCs alongside the T cell lineage.

75.

Nitta, T., Ohigashi, I., Nakagawa, Y. & Takahama, Y. Cytokine crosstalk for thymic medulla formation. Curr. Opin. Immunol. 23, 190–197 (2011).

76.

van Ewijk, W. et al. Thymic microenvironments, 3D versus 2D? Semin. Immunol. 11, 57–64 (1999).

77.

Hun, M. et al. Native thymic extracellular matrix improves in vivo thymic organoid T cell output, and drives in vitro thymic epithelial cell differentiation. Biomaterials 118, 1–15 (2017).

78.

Hussey, G. S., Dziki, J. L. & Badylak, S. F. Extracellular matrix-based supplies for regenerative drugs. Nat. Rev. Mater. three, 159–173 (2018).

79.

Shah, S. B. & Singh, A. Mobile self-assembly and biomaterials-based organoid fashions of improvement and illnesses. Acta Biomater. 53, 29–45 (2017).

80.

Tajima, A. et al. Bioengineering mini purposeful thymic items with EAK16-II/EAKIIH6 self-assembling hydrogel. Clin. Immunol. 160, 82–89 (2015).

81.

Junt, T., Scandella, E. & Ludewig, B. Type follows operate: lymphoid tissue microarchitecture in antimicrobial immune defence. Nat. Rev. Immunol. eight, 764–775 (2008).

82.

Zappasodi, R. et al. The impact of synthetic antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo growth of purposeful human antitumor T cells. Haematologica 93, 1523–1534 (2008).

83.

Li, Y. & Kurlander, R. J. Comparability of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for increasing human T cells: differing influence on CD8 T cell phenotype and responsiveness to restimulation. J. Transl Med. eight, 104 (2010).

84.

Dustin, M. L. The immunological synapse. Most cancers Immunol. Res. 2, 1023–1033 (2014).

85.

Huppa, J. B. & Davis, M. M. T cell-antigen recognition and the immunological synapse. Nat. Rev. Immunol. three, 973–983 (2003).

86.

Mossman, Okay. D., Campi, G., Groves, J. T. & Dustin, M. L. Altered TCR signaling from geometrically repatterned immunological synapses. Science 310, 1191–1193 (2005).

87.

Thery, M. et al. The extracellular matrix guides the orientation of the cell division axis. Nat. Cell Biol. 7, 947–953 (2005).

88.

Coyer, S. R. et al. Nanopatterning reveals an ECM space threshold for focal adhesion meeting and power transmission that’s regulated by integrin activation and cytoskeleton stress. J. Cell Sci. 125, 5110–5123 (2012).

89.

Coyer, S. R., Delamarche, E. & Garcia, A. J. Protein tethering into multiscale geometries by covalent subtractive printing. Adv. Mater. 23, 1550–1553 (2011).

90.

Singh, A. et al. Adhesion strength-based, label-free isolation of human pluripotent stem cells. Nat. Strategies 10, 438–444 (2013).

91.

Dumbauld, D. W. et al. How vinculin regulates power transmission. Proc. Natl Acad. Sci. USA 110, 9788–9793 (2013).

92.

Doh, J. & Irvine, D. J. Immunological synapse arrays: patterned protein surfaces that modulate immunological synapse construction formation in T cells. Proc. Natl Acad. Sci. USA 103, 5700–5705 (2006). On this paper, the authors report on lithographically outlined patterns of T cell receptor ligands surrounded by a area of tethered ICAM1 to imitate T cell–APC interactions.

93.

Shen, Okay., Thomas, V. Okay., Dustin, M. L. & Kam, L. C. Micropatterning of costimulatory ligands enhances CD4+ T cell operate. Proc. Natl Acad. Sci. USA 105, 7791–7796 (2008).

94.

Tan, J. L. et al. Cells mendacity on a mattress of microneedles: an method to isolate mechanical power. Proc. Natl Acad. Sci. USA 100, 1484–1489 (2003).

95.

Fu, J. et al. Mechanical regulation of cell operate with geometrically modulated elastomeric substrates. Nat. Strategies 7, 733–736 (2010).

96.

Basu, R. et al. Cytotoxic T cells use mechanical power to potentiate goal cell killing. Cell 165, 100–110 (2016).

97.

Steenblock, E. R. & Fahmy, T. M. A complete platform for ex vivo T cell growth based mostly on biodegradable polymeric synthetic antigen-presenting cells. Mol. Ther. 16, 765–772 (2008).

98.

Prakken, B. et al. Synthetic antigen-presenting cells as a software to take advantage of the immune ‘synapse’. Nat. Med. 6, 1406 (2000).

99.

Zitvogel, L. et al. Eradication of established murine tumors utilizing a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. Four, 594–600 (1998).

100.

Fadel, T. R. et al. Enhanced mobile activation with single walled carbon nanotube bundles presenting antibody stimuli. Nano Lett. eight, 2070–2076 (2008).

101.

Fadel, T. R. et al. A carbon nanotube-polymer composite for T cell remedy. Nat. Nanotechnol. 9, 639–647 (2014).

102.

Cheung, A. S., Zhang, D. Okay. Y., Koshy, S. T. & Mooney, D. J. Scaffolds that mimic antigen-presenting cells allow ex vivo growth of main T cells. Nat. Biotechnol. 36, 160–169 (2018).

103.

Oelke, M. et al. Ex vivo induction and growth of antigen-specific cytotoxic T cells by HLA-Ig–coated synthetic antigen-presenting cells. Nat. Med. 9, 619 (2003).

104.

Cui, H. F., Vashist, S. Okay., Al-Rubeaan, Okay., Luong, J. H. & Sheu, F. S. Interfacing carbon nanotubes with residing mammalian cells and cytotoxicity points. Chem. Res. Toxicol. 23, 1131–1147 (2010).

105.

Sato, Y. et al. Affect of size on cytotoxicity of multi-walled carbon nanotubes in opposition to human acute monocytic leukemia cell line THP-1 in vitro and subcutaneous tissue of rats in vivo. Mol. Biosyst. 1, 176–182 (2005).

106.

Perica, Okay. et al. Enrichment and growth with nanoscale synthetic antigen presenting cells for adoptive immunotherapy. ACS Nano 9, 6861–6871 (2015).

107.

Smith, M. R., Tolbert, S. V. & Wen, F. Protein-scaffold directed nanoscale meeting of T cell ligands: synthetic antigen presentation with outlined valency, density, and ratio. ACS Synth. Biol. 7, 1629–1639 (2018).

108.

Koffeman, E., Keogh, E., Klein, M., Prakken, B. & Albani, S. Identification and manipulation of antigen particular T cells with synthetic antigen presenting cells. Strategies Mol. Med. 136, 69–86 (2007).

109.

Wherry, E. J. & Kurachi, M. Molecular and mobile insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486–499 (2015).

110.

Lamers, C. H. et al. Remedy of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: scientific analysis and administration of on-target toxicity. Mol. Ther. 21, 904–912 (2013).

111.

Smith, T. T. et al. Biopolymers codelivering engineered T cells and STING agonists can eradicate heterogeneous tumors. J. Clin. Make investments. 127, 2176–2191 (2017).

112.

Stephan, S. B. et al. Biopolymer implants improve the efficacy of adoptive T cell remedy. Nat. Biotechnol. 33, 97–101 (2015).

113.

Allen, C. D., Okada, T. & Cyster, J. G. Germinal-center group and mobile dynamics. Immunity 27, 190–202 (2007).

114.

De Silva, N. S. & Klein, U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 15, 137–148 (2015).

115.

McHeyzer-Williams, M., Okitsu, S., Wang, N. & McHeyzer-Williams, L. Molecular programming of B cell reminiscence. Nat. Rev. Immunol. 12, 24–34 (2012). On this Assessment, the authors talk about every part of antigen-specific B cell improvement and affinity maturation of reminiscence B cells.

116.

Grilo, A. L. & Mantalaris, A. The more and more human and worthwhile monoclonal antibody market. Tendencies Biotechnol. 37, 9–16 (2019).

117.

Yokoyama, W. M. et al. Manufacturing of monoclonal antibodies. Curr. Protoc. Immunol. 102, 2.5.1–2.5.29 (2013).

118.

Georgiou, G. et al. The promise and problem of high-throughput sequencing of the antibody repertoire. Nat. Biotechnol. 32, 158–168 (2014).

119.

Rathmell, J. C. et al. CD95 (Fas)-dependent elimination of self-reactive B cells upon interplay with CD4+ T cells. Nature 376, 181–184 (1995).

120.

Wu, Y. et al. Immune complex-bearing follicular dendritic cells ship a late antigenic sign that promotes somatic hypermutation. J. Immunol. 180, 281–290 (2008).

121.

Pound, J. D. & Gordon, J. Upkeep of human germinal middle B cells in vitro. Blood 89, 919–928 (1997).

122.

Arpin, C. et al. Technology of reminiscence B cells and plasma cells in vitro. Science 268, 720–722 (1995).

123.

Nojima, T. et al. In-vitro derived germinal centre B cells differentially generate reminiscence B or plasma cells in vivo. Nat. Commun. 2, 465 (2011).

124.

Beguelin, W. et al. EZH2 allows germinal centre formation via epigenetic silencing of CDKN1A and an Rb-E2F1 suggestions loop. Nat. Commun. eight, 877 (2017). On this research, the authors develop immune organoids to disclose the epigenetic mechanism behind B cell hyperproliferation in response to an infection.

125.

Roh, Okay. H. et al. An artificial stroma-free germinal middle area of interest for environment friendly technology of humoral immunity ex vivo. Biomaterials 164, 106–120 (2018).

126.

Purwada, A. & Singh, A. Immuno-engineered organoids for regulating the kinetics of B cell improvement and antibody manufacturing. Nat. Protoc. 12, 168–182 (2017).

127.

Purwada, A. et al. Ex vivo engineered immune organoids for managed germinal middle reactions. Biomaterials 63, 24–34 (2015).

128.

Apoorva, F. N. U. et al. Lymph node stiffness-mimicking hydrogels regulate human B cell lymphoma progress and cell floor receptor expression in a molecular subtype-specific method. J. Biomed. Mater. Res. A 105, 1833–1844 (2017).

129.

Cayrol, F. et al. Integrin αvβ3 performing as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood 125, 841–851 (2015).

130.

Tian, Y. F. et al. Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. Biomaterials 73, 110–119 (2015).

131.

Purwada, A. et al. Ex vivo artificial immune tissues with T cell indicators for differentiating antigen-specific, excessive affinity germinal middle B cells. Biomaterials 198, 27–36 (2019). On this paper, the authors reveal that ex vivo 3D immune organoids can kind antigen-specific B cells in a dish.

132.

Purwada, A., Shah, S. B., Beguelin, W., Melnick, A. M. & Singh, A. Modular immune organoids with integrin ligand specificity differentially regulate ex vivo B cell activation. ACS Biomater. Sci. Eng. three, 214–225 (2017).

133.

Apoorva, F. et al. How biophysical forces regulate human B cell lymphomas. Cell Rep. 23, 499–511 (2018).

134.

Hoch, S., Boyd, M., Malone, B., Gonye, G. & Schwaber, J. Fas-mediated apoptosis eliminates B cells that purchase self-reactivity in the course of the germinal middle response to NP. Cell. Immunol. 203, 103–110 (2000).

135.

Meyer-Hermann, M. et al. A idea of germinal middle B cell choice, division, and exit. Cell Rep. 2, 162–174 (2012).

136.

Jones, G. W., Hill, D. G. & Jones, S. A. Understanding immune cells in tertiary lymphoid organ improvement: it’s all beginning to come collectively. Entrance. Immunol. 7, 401 (2016).

137.

Mueller, C. G., Nayar, S., Gardner, D. & Barone, F. Mobile and vascular elements of tertiary lymphoid buildings. Strategies Mol. Biol. 1845, 17–30 (2018).

138.

Nerviani, A. & Pitzalis, C. Function of chemokines in ectopic lymphoid buildings formation in autoimmunity and most cancers. J. Leukoc. Biol. 104, 333–341 (2018).

139.

Rangel-Moreno, J. et al. The event of inducible bronchus-associated lymphoid tissue is dependent upon IL-17. Nat. Immunol. 12, 639–646 (2011).

140.

Dorraji, S. E. et al. Mesenchymal stem cells and T cells within the formation of tertiary lymphoid buildings in lupus nephritis. Sci. Rep. eight, 7861 (2018).

141.

Figenschau, S. L. et al. ICAM1 expression is induced by proinflammatory cytokines and related to TLS formation in aggressive breast most cancers subtypes. Sci. Rep. eight, 11720 (2018).

142.

Vu Van, D. et al. Native T/B cooperation in infected tissues is supported by T follicular helper-like cells. Nat. Commun. 7, 10875 (2016).

143.

Cheng, J. et al. Ectopic B cell clusters that infiltrate transplanted human kidneys are clonal. Proc. Natl Acad. Sci. USA 108, 5560–5565 (2011).

144.

Mittal, S. et al. Lymphoid aggregates that resemble tertiary lymphoid organs outline a selected pathological subset in metal-on-metal hip replacements. PLOS ONE eight, e63470 (2013).

145.

Akhavanpoor, M. et al. Adventitial tertiary lymphoid organ classification in human atherosclerosis. Cardiovasc. Pathol. 32, eight–14 (2018).

146.

Neyt, Okay., Perros, F., GeurtsvanKessel, C. H., Hammad, H. & Lambrecht, B. N. Tertiary lymphoid organs in an infection and autoimmunity. Tendencies Immunol. 33, 297–305 (2012).

147.

Yin, C., Mohanta, S., Maffia, P. & Habenicht, A. J. Editorial: tertiary lymphoid organs (TLOs): powerhouses of illness immunity. Entrance. Immunol. eight, 228 (2017).

148.

Ventura Ferreira, M. S. et al. An engineered multicomponent bone marrow area of interest for the recapitulation of hematopoiesis at ectopic transplantation websites. J. Hematol. Oncol. 9, Four (2016).

149.

Kobayashi, Y. & Watanabe, T. Gel-trapped lymphorganogenic chemokines set off synthetic tertiary lymphoid organs and mount adaptive immune responses in vivo. Entrance. Immunol. 7, 316 (2016).

150.

Ali, O. A., Huebsch, N., Cao, L., Dranoff, G. & Mooney, D. J. An infection-mimicking supplies to program dendritic cells in situ. Nat. Mater. eight, 151–158 (2009).

151.

Singh, A. et al. An injectable artificial immune-priming middle mediates environment friendly T cell class switching and T-helper 1 response in opposition to B cell lymphoma. J. Management. Launch 155, 184–192 (2011).

152.

Calvi, L. M. et al. Osteoblastic cells regulate the haematopoietic stem cell area of interest. Nature 425, 841–846 (2003).

153.

Ding, L. & Morrison, S. J. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature 495, 231–235 (2013).

154.

Matsuda, N., Shimizu, T., Yamato, M. & Okano, T. Tissue engineering based mostly on cell sheet expertise. Adv. Mater. 19, 3089–3099 (2007).

155.

DeForest, C. A. & Anseth, Okay. S. Cytocompatible click-based hydrogels with dynamically tunable properties via orthogonal photoconjugation and photocleavage reactions. Nat. Chem. three, 925–931 (2011).

156.

DeForest, C. A., Polizzotti, B. D. & Anseth, Okay. S. Sequential click on reactions for synthesizing and patterning three-dimensional cell microenvironments. Nat. Mater. eight, 659–664 (2009). On this research, the authors reveal direct fabrication of biologically functionalized gels with photopatterned buildings within the presence of cells — a primary step in the direction of 4D cultures.

157.

Kloxin, A. M. et al. Responsive tradition platform to look at the affect of microenvironmental geometry on cell operate in 3D. Integ. Biol. Four, 1540–1549 (2012).

158.

Hasani-Sadrabadi, M. M. et al. Mechanobiological mimicry of helper T lymphocytes to judge cell–biomaterials crosstalk. Adv. Mater. 30, 1706780 (2018).

159.

Shifrut, E. et al. Genome-wide CRISPR screens in main human T cells reveal key regulators of immune operate. Cell 175, 1958–1971 (2018).

160.

Roth, T. L. et al. Reprogramming human T cell operate and specificity with non-viral genome focusing on. Nature 559, 405–409 (2018).

161.

Dudda, J. C. et al. MicroRNA-155 is required for effector CD8+ T cell responses to virus an infection and most cancers. Immunity 38, 742–753 (2013).

162.

Shin, S. R. et al. Carbon nanotube bolstered hybrid microgels as scaffold supplies for cell encapsulation. ACS Nano 6, 362–372 (2012).

163.

Dvir, T. et al. Nanowired three-dimensional cardiac patches. Nat. Nanotechnol. 6, 720–725 (2011).

164.

Lardner, A. The consequences of extracellular pH on immune operate. J. Leukoc. Biol. 69, 522–530 (2001).

165.

Carswell, Okay. S. & Papoutsakis, E. T. Extracellular pH impacts the proliferation of cultured human T cells and their expression of the interleukin-2 receptor. J. Immunother. 23, 669–674 (2000).

166.

Patel, A. et al. Extremely elastomeric poly(glycerol sebacate)-co-poly(ethylene glycol) amphiphilic block copolymers. Biomaterials 34, 3970–3983 (2013).

167.

Roybal, Okay. T. & Lim, W. A. Artificial immunology: hacking immune cells to develop their therapeutic capabilities. Annu. Rev. Immunol. 35, 229–253 (2017).

168.

Wu, C. Y., Rupp, L. J., Roybal, Okay. T. & Lim, W. A. Artificial biology approaches to engineer T cells. Curr. Opin. Immunol. 35, 123–130 (2015).

169.

Xie, M. & Fussenegger, M. Designing cell operate: meeting of artificial gene circuits for cell biology purposes. Nat. Rev. Mol. Cell Biol. 19, 507–525 (2018).

170.

La Motte-Mohs, R. N., Herer, E. & Zuniga-Pflucker, J. C. Induction of T cell improvement from human wire blood hematopoietic stem cells by Delta-like 1 in vitro. Blood 105, 1431–1439 (2005).

171.

Grakoui, A. et al. The immunological synapse: a molecular machine controlling T cell activation. Science 285, 221 (1999). This work demonstrates that immunological synapse formation is a multistage course of, wherein T cell activation is reconstituted by interacting with MHC–peptide and the adhesion ligand ICAM1.

172.

Doh, J. & Irvine, D. J. Photogenerated polyelectrolyte bilayers from an aqueous-processible photoresist for multicomponent protein patterning. J. Am. Chem. Soc. 126, 9170–9171 (2004).

173.

Bashour, Okay. T. et al. CD28 and CD3 have complementary roles in T cell traction forces. Proc. Natl Acad. Sci. USA 111, 2241–2246 (2014).

174.

Moon, J. J. et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that develop Tfh cells and promote germinal middle induction. Proc. Natl Acad. Sci. USA 109, 1080–1085 (2012).


Supply hyperlink
asubhan

wordpress autoblog

amazon autoblog

affiliate autoblog

wordpress web site

web site improvement

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close